KEFTAB
LOE ApproachingNDAORALTABLET
Approved
Oct 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEFTAB is an oral tablet small-molecule antibiotic approved by Eli Lilly in 1987. The drug's specific mechanism of action and indications are not detailed in available data, but its tablet formulation suggests oral administration for systemic bacterial infections. As a legacy oral antibiotic product, it represents a mature class with significant generic competition.
LOE Approaching
As a legacy antibiotic approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely in managed decline or repositioning mode with limited expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on KEFTAB offers limited career acceleration due to the product's mature lifecycle, approaching loss of exclusivity, and minimal linked job openings. Career value lies in managed decline execution, contract negotiation, and operational cost management rather than growth or innovation.
Brand ManagerSales Representative
Worked on KEFTAB at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.